1 |
Béné MC. Issue Highlights-September 2021. Cytometry B Clin Cytom 2021;100:537-40. [PMID: 34536066 DOI: 10.1002/cyto.b.22031] [Reference Citation Analysis]
|
2 |
Yang Y, Ding R, Wang R. Identification of candidate targets and mechanisms involved in miRNA regulation in multiple myeloma. World J Surg Onc 2022;20. [DOI: 10.1186/s12957-021-02482-1] [Reference Citation Analysis]
|
3 |
Maclachlan KH, Came N, Diamond B, Roshal M, Ho C, Thoren K, Mayerhoefer ME, Landgren O, Harrison S. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology 2021;53:385-99. [PMID: 33674146 DOI: 10.1016/j.pathol.2021.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
4 |
Brestoff JR, Frater JL. Contemporary Challenges in Clinical Flow Cytometry: Small Samples, Big Data, Little Time. The Journal of Applied Laboratory Medicine 2022. [DOI: 10.1093/jalm/jfab176] [Reference Citation Analysis]
|
5 |
Riva G, Nasillo V, Ottomano AM, Bergonzini G, Paolini A, Forghieri F, Lusenti B, Barozzi P, Lagreca I, Fiorcari S, Martinelli S, Maffei R, Marasca R, Potenza L, Comoli P, Manfredini R, Tagliafico E, Trenti T, Luppi M. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers (Basel) 2021;13:4582. [PMID: 34572809 DOI: 10.3390/cancers13184582] [Reference Citation Analysis]
|